13D Filing: OrbiMed Advisors and Intellia Therapeutics Inc (NTLA)

Page 2 of 13 – SEC Filing

SCHEDULE 13D
CUSIP No.  45826J105
Page 2 of 15 Pages
1
NAME OF REPORTING PERSONS
OrbiMed Advisors LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)
(b)
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
2,537,684
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
2,537,684
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,537,684
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions)
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.99%*
14
TYPE OF REPORTING PERSON (See Instructions)
IA
_______________________
* This percentage is calculated based upon 42,335,266 shares of Common Stock outstanding of the Issuer, as set forth in the Issuer’s Prospectus Supplement, filed with the Securities and Exchange Commission on November 3, 2017.
Follow Intellia Therapeutics Inc. (NASDAQ:NTLA)